Multicenter Non-Therapeutic Study of Infliximab for Severe Refractory Colitis in Hospitalized Children
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 7
- 主要终点
- The primary endpoint will be the relationship between IFX exposure (area under the curve of the PK model) and Day 7 clinical response defined as Pediatric Ulcerative Colitis Activity Index (PUCAI) <35.
研究概览
简要总结
This multicenter study is being conducted to determine whether infliximab exposure after an initial infusion is predictive of early clinical response in hospitalized pediatric patients with severe steroid-refractory UC or IBD-U. This pilot and feasibility study will establish the infrastructure, demonstrate feasibility, and collect preliminary data to support the full study.
详细描述
This is a multicenter prospective non-interventional cohort study to identify clinical and biological markers that predict non-response in hospitalized pediatric patients with severe corticosteroid-refractory UC or inflammatory bowel disease unspecified (IBD-U) being initiated on infliximab.
Patients hospitalized with severe UC or IBD-U (PUCAI ≥ 65 on admission) and failing intravenous corticosteroids will be eligible. Blood, stool, and rectal biopsies (if sigmoidoscopy performed for clinical indications) will be collected for translational studies (Aim 3). Patients will receive infliximab per the dose and regimen determined by clinical physician. No standard dosing regimen will be used and the dose of IFX will be determined by the treating physician. Serial PUCAI scores and infliximab levels will be obtained.
Those who are eligible to participate will have serial blood samples taken in association with drug infusions to perform pharmacokinetic/pharmacodynamic modeling of infliximab exposure. Clinical response will be determined using the Pediatric UC Activity Index (PUCAI) questionnaire.
Initially, 6 centers will participate with a minimum target enrollment goal of 36 evaluable pediatric research participants (to a maximum of 40) age > 4 years or < 18 years old with UC or IBD-U (average 6/center).
The primary endpoint will be the relationship between IFX exposure (area under the curve of the PK model) and Day 7 clinical response defined as Pediatric Ulcerative Colitis Activity Index (PUCAI) ≤ 35. Secondary endpoints will be Week 8 clinical remission, and Week 26 steroid-free, colectomy-free remission. We will initially enlist 6 centers, and enroll 36-40 evaluable patients in 2 years.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 4 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age criteria: ≥ 4 or < 18 years of age
- •Diagnosis of UC or IBD-U by established criteria
- •Admitted to the hospital
- •Colitis extending beyond the rectosigmoid colon
- •PUCAI ≥ 65 at admission and ≥ 45 at first dose of infliximab
- •Treatment with infliximab considered by the treating physician
- •Anticipated follow-up ≥ 6 months from infliximab initiation
- •Permission/assent of parent/guardian and research participant.
排除标准
- •Diagnosis of Crohn's disease
- •Enteric infection with a bacterial pathogen (including clostridium difficile), per review of medical records
- •Colon tissue positive for CMV by PCR, immunohistochemistry, or in situ hybridization, per review of the medical records
- •Colitis currently extending only to the rectosigmoid colon (proctosigmoiditis)
- •Prior treatment with infliximab or other anti-TNF agent
- •Prior treatment with cyclosporine or tacrolimus
- •PUCAI < 45 the day of first infliximab infusion
- •Pregnancy, per review of medical records and verbal report
- •Other poorly controlled medical condition
- •Hepatic disease (AST or Alk Phos > 3 times the upper limit of normal) in the absence of IBD associated liver disease
- •Renal disease (BUN and creatinine >1.5 times the upper limit of normal)
结局指标
主要结局
The primary endpoint will be the relationship between IFX exposure (area under the curve of the PK model) and Day 7 clinical response defined as Pediatric Ulcerative Colitis Activity Index (PUCAI) <35.
时间窗: 7 days
IFX exposure and Day 7 PUCAI
次要结局
未报告次要终点